NorDiag is pleased to announce that it has granted Fisher Healthcare, part of Thermo Fisher Scientific, a non-exclusive distribution agreement for its Arrow and Bullet products in the United States for the molecular diagnostics and medical research laboratory markets. The agreement is effective from July 1, 2010.

"We have been looking for a leading broad based distribution partner for the NorDiag products within the US and are delighted to have reached this agreement with Fisher Healthcare, the market leader for distributing products serving the clinical market within the US", comments Mårten Wigstøl, CEO of NorDiag.

NorDiag's medium/high throughput instrument, Bullet has the capacity of up to 100,000 isolations per year. NorDiag's low throughput instrument, Arrow has the capacity of up to 10,000 isolations per year.
 
Contact:
CEO Mårten Wigstøl, Phone + 47 911 65775

Read the notice in Norwegian here.